Becton, Dickinson and Company logo

Becton, Dickinson and Company (BDX)

Market Closed
16 Jul, 20:00
XMEX XMEX
MX$
2,683. 83
0
0%
MX$
- Market Cap
- P/E Ratio
4.2% Div Yield
40 Volume
- Eps
MX$ 2,683.83
Previous Close
Add Transaction
Day Range
2,683.83 2,683.83
Year Range
2,498.49 3,535.21
Want to track BDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BDX closed Thursday higher at MX$2,683.83, an increase of 0% from Wednesday's close, completing a monthly increase of 0% or MX$0. Over the past 12 months, BDX stock lost -24.0829%.
BDX pays dividends to its shareholders, with the most recent payment made on Jun 30, 2026. The next estimated payment will be in In 2 months on Sep 30, 2026 for a total of MX$1.05.
The last earnings report, released on Apr 29, 2026, missed the consensus estimates by -3.33%. On average, the company has fell short of earnings expectations by -2.0367%, based on the last three reports.
Becton, Dickinson and Company has completed 6 stock splits, with the recent split occurring on Feb 10, 2026.
The company's stock is traded on 13 different exchanges and in various currencies, with the primary listing on NYSE (USD).

BDX Chart

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report?

Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 1 week ago
Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There

Becton, Dickinson - Stable Undervaluation In 1Q26, Upside Is There

Becton, Dickinson and Company is undervalued, trading at 12–13x P/E despite forecasted 7%–8% annual growth and improving fundamentals. BDX's sector-wide pressures are driven by cautious hospital spending, higher rates, and capital rotation into AI, but its core operations remain robust. BDX maintains a BBB rating, conservative leverage, a 2.78% dividend with 44+ years of increases, and is executing $2B in buybacks while retiring $2.1B in debt.

Seekingalpha | 2 weeks ago
Here's Why You Should Retain BDX Stock in Your Portfolio Now

Here's Why You Should Retain BDX Stock in Your Portfolio Now

Becton, Dickinson's MedTech focus, innovation push and strategic partnerships support growth optimism, though reimbursement uncertainty remains a key concern.

Zacks | 1 month ago

Becton, Dickinson and Company (BDX) FAQ

What is the stock price today?

The current price is MX$2,683.83.

On which exchange is it traded?

Becton, Dickinson and Company is listed on XMEX.

What is its stock symbol?

The ticker symbol is BDX.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 4.2%.

What is its market cap?

As of today, no market cap data is available.

Has Becton, Dickinson and Company ever had a stock split?

Becton, Dickinson and Company had 6 splits and the recent split was on Feb 10, 2026.

Becton, Dickinson and Company Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Thomas E. Polen Jr. CEO
XMEX Exchange
US0758871091 ISIN
US Country
70,000 Employees
9 Jun 2026 Last Dividend
10 Feb 2026 Last Split
- IPO Date

Overview

Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.

Products and Services

  • BD Medical:

    This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.

  • BD Life Sciences:

    In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.

  • BD Interventional:

    BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.

Contact Information

Address: 1 Becton Drive
Phone: 201 847 6800